Among patients with curatively resected early-stage biliary tract cancer (BTC), recent study findings from a real-world cohort trial revealed the value of circulating tumor DNA (ctDNA) as a prognostic ...

At ctDNA levels below 10 mutant copies/mL (0.25% VAF) it can reassure patients that progression is unlikely, while levels above 100 copies/mL (2.5% VAF) are associated with at least a 90% chance ...

circulating tumor DNA (ctDNA), which is released into the bloodstream by tumor cells, offers a promising non-invasive alternative. It allows for real-time monitoring and comprehensive genetic ...

Natera (NTRA) announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA or ctDNA. This builds on ...

National Comprehensive Cancer Network® (NCCN®) Guidelines for colon and rectal cancer were updated to include ctDNA as a prognostic marker and high risk factor for recurrence NCCN guideline for ...

ctDNA offers a non-invasive way to track Multiple Myeloma, reducing the need for painful bone marrow biopsies Detects genetic mutations, treatment resistance, and disease progression before ...